Independent
Tenure on this board
4.0 yrs
2 nominees · 4 ballot items.
Election of two Class I directors; advisory vote to approve named executive officer compensation (say-on-pay); ratification of Ernst & Young LLP as independent registered public accounting firm; and approval of a fourth amendment to the 2022 Stock Option and Incentive Plan to increase authorized shares by 7,000,000.
Elect two Class I director nominees, J. Martin Carroll and Sheldon L. Koenig, each for a three-year term ending at the 2029 Annual Meeting.
Non-binding advisory (say-on-pay) vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
This management proposal requests a non-binding advisory vote (a 'say-on-pay') approving the overall compensation of the company’s named executive officers as disclosed in the proxy statement. Management and the compensation committee present this vote to provide stockholders a periodic opportunity to express their view on pay practices and alignment between executive pay and company performance. The company describes its program as designed to attract and retain key executives, reward both short-term and long-term performance, and align executive financial interests with stockholder interests through a mix of cash incentive awards and equity grants that vest over multiple years. The advisory nature means the Board is not required to change compensation based on the result, but the Board and compensation committee state they will carefully consider stockholder feedback when making future decisions. Contextually, the company emphasizes achievement of corporate goals (including U.S. net sales and pipeline progress) and used a corporate performance-based cash incentive in 2025; the Board also notes engagement with investors and adjustments tied to peer benchmarking. Potential investor concerns include the prevalence of time-based versus performance-based equity, overall quantum of awards relative to company performance and dilution from equity programs; management has signaled responsiveness to such feedback. The Board recommends a vote FOR, citing the program’s design to balance measured compensation with incentives to enhance long-term stockholder value and retain talent in a competitive biopharma market. In evaluating the merits, a sophisticated analyst should weigh the company’s recent operational achievements, the link between pay and disclosed performance metrics, vesting schedules, and expected future dilution from equity grants. Given the advisory nature, the outcome primarily serves as governance feedback rather than a direct contractual change, but a negative result would likely prompt further shareholder engagement and potential plan adjustments by the compensation committee.
Ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Approve a fourth amendment to the 2022 Plan to increase the aggregate number of shares authorized for issuance under the plan by 7,000,000 shares (increasing the total to 30,150,000 shares).
Management is asking stockholders to approve a one-time 7,000,000-share increase to the company’s 2022 Stock Option and Incentive Plan to replenish the share reserve used for equity-based compensation. Management explains that share usage has accelerated due to hiring, annual grant practices, and stock-price volatility that raises the number of shares required to deliver competitive award values, and that without additional shares the company may be forced to increase cash compensation or otherwise change its incentives. The proposal emphasizes that the 2022 Plan has no automatic “evergreen” refill, so stockholder approval is required to add shares and the Board expects the requested increase to fund awards for roughly the next 12 months. The Board frames the amendment as preserving the ability to attract, retain and motivate employees and directors while arguing that the benefits to stockholders from equity-based incentives outweigh potential dilution; it also notes that the plan prohibits repricing without stockholder approval and contains annual limits and minimum vesting protections. Key governance considerations for analysts include the magnitude of the requested increase relative to outstanding shares and recent dilution trends, the company’s historic burn rate and anticipated grant needs, the absence of an evergreen feature (which gives stockholders periodic oversight), and whether awards are predominantly time‑based or performance‑based. The Board’s recommendation to vote FOR is premised on maintaining a competitive compensation program and avoiding increased cash expense; opponents might focus on dilution, frequency of renewals, and the proportion of equity granted to insiders. A sophisticated evaluation should weigh the company’s stated hiring and retention needs, recent operational performance and cash position, the expected share usage over the next year, and practices (e.g., minimum vesting, repricing restrictions) that mitigate governance risks.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | WASATCH ADVISORS LP | 6.13% | 15,768,897 | $43M |
| 2 | Two Seas Capital LP | 4.43% | 11,394,833 | $31M |
| 3 | ORBIMED ADVISORS LLCActivist | 4.11% | 10,570,300 | $29M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.05% | 10,433,760 | $29M |
| 5 | TWO SIGMA INVESTMENTS, LP | 3.67% | 9,458,779 | $26M |
| 6 | BlackRock, Inc. | 3.48% | 8,971,419 | $25M |
| 7 | BlackRock, Inc. | 2.75% | 7,071,163 | $19M |
| 8 | STATE STREET CORP | 2.74% | 7,055,794 | $19M |
| 9 | D. E. Shaw Co., Inc.Activist | 2.50% | 6,425,512 | $18M |
| 10 | MARSHALL WACE, LLP | 2.49% | 6,422,519 | $18M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.